Biotech Values

[DewDiligence]

FDA grants priority review for ABBV/ENTA 3-DAA HCV regimen:

http://finance.yahoo.com/news/enanta-pharmaceuticals-announces-u-fda-193900398.html

Priority review was expected insofar as the 3-DAA regimen has BTD status. The PDUFA date is on or about 12/21/14 (8 months from the 4/21/14 submission date), although there’s a pretty good chance (IMO) of approval before the deadline.